Cardiovascular pharmacotherapy in patients with marfan syndrome

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


The cardiovascular complications of Marfan syndrome (MFS) remain the primary source of morbidity and mortality in affected patients. Over the last decade, the underlying pathogenesis of these cardiovascular abnormalities has been the focus of much research. Such research has shed light on the potential role of several novel medical therapies and their ability to prevent cardiovascular disease progression. This paper summarizes the research underlying new medical therapies and provides a review of the scientific foundation underlying all current medical therapies used for prevention of cardiovascular disease in patients with MFS, including β-adrenoceptor antagonists, calcium channel antagonists, ACE inhibitors, and angiotensin receptor antagonists.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalAmerican Journal of Cardiovascular Drugs
Issue number2
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Cardiovascular pharmacotherapy in patients with marfan syndrome'. Together they form a unique fingerprint.

Cite this